Literature DB >> 3684399

Ceftriaxone effect on bilirubin-albumin binding.

S Fink1, W Karp, A Robertson.   

Abstract

The effect of ceftriaxone on bilirubin-albumin binding was measured in vitro using the peroxidase method with human serum albumin and a dialysis rate method with adult and newborn serum. Ceftriaxone competes with bilirubin for binding to human serum albumin; the displacement constant is 1.5 X 10(4) L/mol. Therapeutic levels of ceftriaxone decrease the reserve albumin concentration in newborn serum by 39%. These results indicate that ceftriaxone may increase the risk of bilirubin encephalopathy in jaundiced premature infants.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3684399

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease.

Authors:  Kevin A Strauss; Donna L Robinson; Hendrik J Vreman; Erik G Puffenberger; Graham Hart; D Holmes Morton
Journal:  Eur J Pediatr       Date:  2006-01-25       Impact factor: 3.183

3.  In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns.

Authors:  S J Wadsworth; B Suh
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 4.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 5.  Early-onset neonatal sepsis.

Authors:  Kari A Simonsen; Ann L Anderson-Berry; Shirley F Delair; H Dele Davies
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

6.  Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.

Authors:  Michael Schleibinger; Cathérine L Steinbach; Christoph Töpper; Alexander Kratzer; Uwe Liebchen; Frieder Kees; Bernd Salzberger; Martin G Kees
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

Review 7.  Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.

Authors:  Patrick C Donnelly; Rebecca M Sutich; Ryan Easton; Oluwatunmise A Adejumo; Todd A Lee; Latania K Logan
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

8.  Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Authors:  E Martin; S Fanconi; P Kälin; C Zwingelstein; C Crevoisier; W Ruch; R Brodersen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

Review 9.  Efficacy and safety of cefotaxime in the management of pediatric infections.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 10.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.